17,977 results match your criteria: "St. Jude Children's Research Hospital; junmin.peng@stjude.org.[Affiliation]"
Mol Ther
December 2024
Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address:
Ann Hematol
December 2024
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Cell Stem Cell
December 2024
Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Harvard Stem Cell Institute, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Gene editing the BCL11A erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for β-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its safety and efficacy. Here, we compare combined CRISPR-Cas9 editing of the BCL11A +58 and +55 enhancers with leading gene modification approaches under clinical investigation. Dual targeting of the BCL11A +58 and +55 enhancers with 3xNLS-SpCas9 and two single guide RNAs (sgRNAs) resulted in superior HbF induction, including in sickle cell disease (SCD) patient xenografts, attributable to simultaneous disruption of core half E-box/GATA motifs at both enhancers.
View Article and Find Full Text PDFCognit Ther Res
August 2024
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Purpose: This is a secondary analysis of a multi-site, cluster (site) randomized trial of the efficacy of a combined Health and Wellness Cognitive Behavior Therapy (H&W CBT) and medication management approach for depression in youth with HIV (YWH) compared to standard care. In this study, we explored the association between H&W CBT factors and depression outcomes after 24 weeks of treatment to discover treatment elements associated with symptom reduction.
Methods: Participants (12-24 years of age) were YWH in the United States (US) diagnosed with moderate to severe depression [Quick Inventory of Depressive Symptomatology (QIDS), Clinician-Rated score ≥ 11].
Front Hum Neurosci
November 2024
The Loyal and Edith Davis Neurosurgical Research Laboratory, Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States.
Introduction: Brain cross-sectional images, tractography, and segmentation are valuable resources for neuroanatomical education and research but are also crucial for neurosurgical planning that may improve outcomes in cerebellar and brainstem interventions. Although ultrahigh-resolution 7-Tesla (7T) magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) reveal such structural brain details in living or fresh unpreserved brain tissue, imaging standard formalin-preserved cadaveric brain specimens often used for neurosurgical anatomic studies has proven difficult. This study sought to develop a practical protocol to provide anatomic information and tractography results of an human brainstem-cerebellum specimen.
View Article and Find Full Text PDFFront Pediatr
November 2024
Department of Pediatrics, Case Western Reserve University, Cleveland, OH, United States.
Background: Patients with recurrent, chronic, or refractory cytopenias represent a challenging subgroup that may harbor an underlying diagnosis, such as an inborn error of immunity (IEI). Patients with IEIs such as activated phosphoinositide 3-kinase delta syndrome (APDS), frequently have hematologic manifestations, but these are not often reported as presenting symptoms. As a result, IEIs may be overlooked in patients presenting with early and/or recalcitrant cytopenias.
View Article and Find Full Text PDFNature
December 2024
Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, TN, USA.
The automated synthesis of small organic molecules from modular building blocks has the potential to transform our capacity to create medicines and materials. Disruptive acceleration of this molecule-building strategy broadly unlocks its functional potential and requires the integration of many new assembly chemistries. Although recent advances in high-throughput chemistry can speed up the development of appropriate synthetic methods, for example, in selecting appropriate chemical reaction conditions from the vast range of potential options, equivalent high-throughput analytical methods are needed.
View Article and Find Full Text PDFNat Commun
December 2024
Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.
Vaccine
January 2025
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
J Pediatr Pharmacol Ther
December 2024
Department of Pharmacy and Pharmaceutical Sciences (DAA, DA), St. Jude Children's Research Hospital, Memphis, TN.
Proteomics
January 2025
Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Advances in high-throughput omics technologies have enabled system-wide characterization of biological samples across multiple molecular levels, such as the genome, transcriptome, and proteome. However, as sample sizes rapidly increase in large-scale multi-omics studies, sample mix-ups have become a prevalent issue, compromising data integrity and leading to erroneous conclusions. The interconnected nature of multi-omics data presents an opportunity to identify and correct these errors.
View Article and Find Full Text PDFAm J Health Syst Pharm
January 2025
Chief Clinical Operating Officer, Eskenazi Health, Indianapolis, IN, USA.
Pediatr Blood Cancer
March 2025
Division of Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Background: Sinusoidal obstruction syndrome (SOS), a serious complication after hematopoietic cell transplant (HCT), is associated with multiorgan dysfunction (MOD) and a high mortality rate. In severe cases, continuous kidney replacement therapy (CKRT) is initiated to manage fluid overload (FO) and acute kidney injury. Studies that evaluate the use of CKRT in this population are lacking.
View Article and Find Full Text PDFBMJ Lead
December 2024
Institute for Healthcare Improvement, Boston, Massachusetts, USA.
J Clin Oncol
December 2024
Department of Pediatric Oncology, University of Minnesota, Minneapolis, MN.
Purpose: The TRK inhibitor larotrectinib is US Food and Drug Administration approved for fusion-positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed fusion-positive solid tumors with response-adapted duration of therapy and local control.
Methods: Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability.
N Engl J Med
December 2024
From the Division of Haematology-Oncology (S.G., S.A., S.Z.), the Faculty of Medicine (S.G., S.A.), and the Department of Laboratory Medicine and Pathobiology, University of Toronto (M.S.), Toronto, and British Columbia Children's Hospital, University of British Columbia, Vancouver (A.M.L.) - all in Canada; Seattle Children's Hospital (R.E.R., T.H.-W., M.L.L.), the Ben Towne Center for Childhood Cancer and Blood Disorders Research and the Department of Pediatrics, Fred Hutchinson Cancer Center, University of Washington (R.E.R., M.L.L.), and Adaptive Biotechnologies (I.K.) - all in Seattle; the Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville (J.A.K., C.W., S.C.); the Division of Pediatric Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston (K.R.R.), Children's Blood and Cancer Center and Dell Children's Medical Center of Central Texas, Austin (H.R.K.), and the Department of Pediatrics, Division of Pediatric Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas (N.W.) - all in Texas; Servier Pharmaceuticals, Boston (A.L.A.); the Department of Genetics, University of Alabama at Birmingham, Birmingham (A.J.C.); Children's Hospital Colorado and the University of Colorado School of Medicine, Aurora (L.G., M.M.O.); the Division of Pediatric Hematology-Oncology, University of Utah, Primary Children's Hospital, Salt Lake City (J.L.M.); the Children's Oncology Group, Monrovia (O.M.), the Department of Pediatric Hematology-Oncology, MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach (M.O.), the Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles (B.L.W.), and Amgen, Thousand Oaks (F.Z.) - all in California; the Department of Pediatrics, Emory University School of Medicine, Atlanta (T.P.M.); the Steve and Cindy Rasmussen Institute for Genomic Medicine and the Biopathology Center, Nationwide Children's Hospital (S.C.R.) and the Biopathology Center and Children's Oncology Group Biospecimen Bank, Nationwide Children's Hospital (Y.M., E.W.) - both in Columbus, OH; Amgen Research, Munich, Germany (G.Z.); the Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN (M.D.); the Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania - both in Philadelphia (S.P.H., D.T.T.); and the Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York (E.A.R.).
Background: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.
View Article and Find Full Text PDFVaccine
February 2025
St. Jude Children's Research Hospital, Department of Epidemiology and Cancer Control, 262 Danny Thomas Place, Memphis, TN 38105, USA. Electronic address:
Geographical disparities exist in human papillomavirus (HPV) vaccination rates with Southern states having the lowest rates. Parental attitudes remain understudied in different Southern locations. We assessed factors related to HPV vaccination receipt among children aged 9-17 years in Tennessee, and if those factors differed by child's age and gender.
View Article and Find Full Text PDFExp Hematol
December 2024
St. Jude Children's Research Hospital, Memphis, TN. Electronic address:
Cell Stem Cell
December 2024
National Heart, Lung, and Blood Institute (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD 20814, USA. Electronic address:
Editing the +58 region of the BCL11A erythroid enhancer has shown promise in treating β-globin disorders. To address variations in fetal hemoglobin (HbF) response, we investigated editing both +58 and +55 enhancers. Rhesus macaques transplanted with edited hematopoietic stem/progenitor cells (HSPCs) following busulfan conditioning exhibited durable, high-level (∼90%) editing frequencies post transplantation with sustained HbF reactivation over 4 years, without hematological perturbations.
View Article and Find Full Text PDFNat Commun
December 2024
Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Neurodevelopmental disorders are thought to arise from intrinsic brain abnormalities. Alternatively, they may arise from disrupted crosstalk among tissues. Here we show the local reduction of two vestibulo-cerebellar lobules, the paraflocculus and flocculus, in mouse models and humans with 22q11.
View Article and Find Full Text PDFMetabolomics
December 2024
Division of Systems Biology, National Center for Toxicological Research, United States Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, 72079, USA.
Introduction: Coronavirus disease 2019 (COVID-19) has widely varying clinical severity. Currently, no single marker or panel of markers is considered standard of care for prediction of COVID-19 disease progression. The goal of this study is to gain mechanistic insights at the molecular level and to discover predictive biomarkers of severity of infection and outcomes among COVID-19 patients.
View Article and Find Full Text PDFVirchows Arch
December 2024
Department of Pathology, MS 250, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN, 38105, USA.
Soft tissue myoepithelial tumors (METs) are diagnostically challenging tumors that require careful histologic and immunohistochemical characterization for accurate classification. Nearly half of METs show recurrent EWSR1 or FUS gene rearrangements with a diverse set of fusion partners. The diversity of fusion partners and lack of known driver abnormalities in many cases raises the question of whether METs represent a uniformly distinct tumor entity.
View Article and Find Full Text PDFAm J Public Health
January 2025
Heather M. Brandt is with the HPV Cancer Prevention Program, St. Jude Children's Research Hospital, Memphis, TN. Laura M. Schwab-Reese is with the Department of Public Health, Purdue University, West Lafayette, IN. Casper Voyles is with the Department of Social Justice and Social Change, Hamline University, St. Paul, MN. M. Aaron Guest is with the Center for Innovation in Healthy and Resilient Aging, Arizona State University, Phoenix. Amy Hagopian is with the Department of Global Health and Department of Health Systems and Population Health, University of Washington, Seattle. At the time of conceptualization, H. M. Brandt, L. M. Schwab-Reese, and A. Hagopian were members of the AJPH Editorial Board, and C. Voyles and A. Guest were leaders in the LGBTQ Health Caucus in official relations with the American Public Health Association.
Sci Transl Med
December 2024
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Neurological injury drives most deaths and morbidity among patients hospitalized for out-of-hospital cardiac arrest (OHCA). Despite its clinical importance, there are no effective pharmacological therapies targeting post-cardiac arrest (CA) neurological injury. Here, we analyzed circulating immune cells from a large cohort of patients with OHCA, finding that lymphopenia independently associated with poor neurological outcomes.
View Article and Find Full Text PDFJ Appl Stat
April 2024
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.